We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Technique Detects Down Syndrome in Fetuses in Two Hours

By Biotechdaily staff writers
Posted on 27 Aug 2007
A new technique enables pregnant women to know whether their fetus has Down syndrome in just a few hours.

Called FlashFISH, the new technique is a modification of the existing standard fluorescence in situ hybridization (FISH) test, which provides results in 24-48 hours. More...
Another procedure, called karyotyping, delivers results between eight and 21 days.

Both FlashFISH and the standard FISH involve inserting a needle through the pregnant woman's abdominal wall to draw amniotic fluid from the womb. The amniotic fluid comes from the membranous sac, which surrounds the embryo and contains genetic material from the fetus. The FlashFISH test requires only two ml of fluid compared with 5 ml needed for standard tests. Clinicians examine fetal cells in the fluid by maneuvering a molecular probe directly into the cells' nucleus. The probe is a tiny portion of DNA that can attach to a matching sequence in the fetal cell and identify whether it is abnormal.

The new procedure was developed by assistant Prof. Mahesh Choolani, from the department of obstetrics and gynecology, National University of Singapore (NUS; Singapore), and his laboratory team. Dr Choolani reported that FlashFISH matches the accuracy of the currently used standard FISH test. He added that it poses no additional risks to the mother and costs roughly the same amount as the currently used test.

Prof. Choolani said that the test has proved to be 99% accurate in detecting Down syndrome. The new technique carries the same risk of miscarriage--about one in 100--as the traditional tests because it involves inserting a needle into the womb.

The test particularly will be useful for women who become pregnant after age 35 because they are more at risk for having a child with Down syndrome. Prof. Choolani said that they had decided to develop a faster test because, Waiting for test results can cause a lot of anxiety in couples.


Related Links:
National University of Singapore

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.